Spyre rises after bowel disease drug succeeds in mid-stage study

Spyre Therapeutics

13/04/2026 16:34

Updates

** Shares of drug developer Spyre Therapeutics SYRE.O rise 19.8% to an over four-year high of $61.42, snapping a two-day losing streak

** SYRE says its experimental drug showed a significant reduction in disease activity in a mid-stage study in patients with ulcerative colitis

** The drug, SPY001, met the main goal of the trial, reducing a key measure of tissue-level inflammation after 12 weeks of treatment, co says

** Ulcerative colitis is a chronic inflammatory disease causing swelling and ulcers in the lining of the colon and rectum

** As of last close, SYRE stock was up 56% YTD

 (Reporting by Padmanabhan Ananthan and Kamal Choudhury)

 ((Padmanabhan.Ananthan@thomsonreuters.com))